Formatted for Registrations
GRASP is partnering with the conference on Advancing the Science of Cancer in Latinos and offering our signature Poster Walkthrough in person in San Antonio at the ASCL poster session on February 22. This Poster Walkthrough is being offered exclusively for members of the Latino Patient Advocate Training program (LPAT). LPAT members do not need to register as that being done on the backend.
Morning Session – Wed Jun 12, 2024
All times shown are Eastern Time (US/New York)
Group 1A: Metastatic Breast Cancer; ER+; Biomarkers; Liquid Biopsy; Novel Drug Sold Out
Poster #P4-10-28:Â Efficacy, safety and biomarker results of AC699, a chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer Poster #P1-05-19:Â Circulating Tumor DNA as a Prognostic Biomarker for CDK 4/6 Inhibitor Therapy in Metastatic Breast Cancer
Group 1B: Metastatic Breast Cancer; Pharmacokinetics; Drug Dosing; Triple-Negative Breast Cancer Last Few Tickets
Poster #P1-09-25:Â Population Pharmacokinetics (PopPK) and Exposure- Response (E-R) Analyses of Sacituzumab Govitecan (SG) in Japanese Patients (pts) with Metastatic Triple-Negative Breast Cancer (mTNBC) and other Advanced Solid Tumors Poster #P3-10-18:Â Phase II Single Arm Trial of Low Dose Capecitabine in Patients with Advanced Breast Cancer (NCT06105684)
Group 1C: Metastatic Breast Cancer; HER2+; Antibody Drug Conjugates; Treatment Resistance; Novel Drug Sold Out
Poster #P1-01-27:Â HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer Poster #P2-10-20:Â ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
Group 1D: Early-Stage Breast Cancer; ER+; Risk of Recurrence Sold Out
Poster #P2-10-07: Practice patterns and survival analysis of early-stage HER2-negative breast cancers with low and intermediate levels of hormone receptor expression: a 2018-2020 US National Cancer Database analysis Poster #P4-01-26: The Xpert® Breast Cancer Insight test predicts distant recurrence and overall survival in estrogen receptor-positive, HER2-negative early breast cancer: A validation study in ABCSG Trial 8
Group 1E: Metastatic Breast Cancer; ER+; Novel Drug Sold Out
Poster #P3-03-23: Targeting of SEMA7A Signaling Improves Response to Endocrine Therapy in ER+ BC Poster #P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results
Group 1F: Metastatic Breast Cancer; ER+; Liquid Biopsy; Treatment Resistance Sold Out
Poster #P1-01-26:Â Genomic profiling of ctDNA and association with efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy Poster #P2-07-22:Â Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced […]
Group 1G: Breast cancer; Imaging; Artificial Intelligence Sold Out
Poster #P2-02-30:Â IMC-DINO: A self supervised deep learning approach to highly multiplexed breast cancer imaging Poster #P2-07-03:Â Noninvasive imaging of breast cancer and metastasis using TROP2-targeting radiotracer 68Ga-TTP
Group 1H: Breast Cancer; Inflammation; Supportive Care; Supplements; Fatigue Last Few Tickets
Poster #P5-08-12: Association of Baseline Global Inflammation Score with Clinical Outcomes: Secondary Analysis from Alliance A011502 Poster #P2-12-16:Â A prospective randomized placebo-controlled trial evaluating effect of a wide spectrum micronutrients supplement on cancer related fatigue in breast cancer patients treated with adjuvant/neo-adjuvant therapy
Group 1J: Breast Cancer; Young Women; Psychosocial Needs; Quality of Life
Poster #P2-01-14:Â Impact of Psychological Support on Quality of Life, Coping Strategies, and Anxiety and Depression in Breast Cancer Patients: A Comparative Randomized Stud Poster #P2-03-04:Â Assessing and Addressing the Distinct Psychosocial Needs of Young Women with Breast Cancer
Group 1K: Metastatic Breast Cancer; ER+; Biomarkers; Liquid Biopsy; Novel Drug
Poster #P4-10-28:Â Efficacy, safety and biomarker results of AC699, a chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer Poster #P1-05-19:Â Circulating Tumor DNA as a Prognostic Biomarker for CDK 4/6 Inhibitor Therapy in Metastatic Breast Cancer
No event found!
